Deals
Migraine Drug Developer Biohaven Is Said to Explore Sale
- Drugmaker has attracted interest from potential bidders
- Migraine market has gotten boost from new treatment launches
This article is for subscribers only.
Biohaven Pharmaceutical Holding Co., a developer of migraine treatments, is exploring options including a possible sale of the company after attracting interest from potential bidders, according to people familiar with the matter.
The drugmaker, which is working with a financial adviser, is in the early stages of considering a sale or partnerships and the talks may not lead to a deal, said the people, who asked not to be identified as the details aren’t public.